

Curriculum Vitae

Doo-Sik Kong M.D., Ph.D.

Professor
Department of Neurosurgery
Samsung Medical Center
Sungkyunkwan University School of medicine
Seoul, Korea



Mailing address

81, Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea
Phone: 82-2-3410-0732
Fax: 82-2-3410-0048
E-mail: neurokong@gmail.com / kds026@skku.edu

Administrative Appointments

Professor, Samsung Medical Center, Sungkyunkwan University, 2019-
Associate Professor, Samsung Medical Center, Sungkyunkwan University, 2013-2019
Assistant Professor, Samsung Medical Center, Sungkyunkwan University, 2009 – 2012
Clinical assistant Professor, Department of Neurosurgery, Samsung Medical Center, 2008-2009
Clinical instructor, Samsung Medical Center, 2007-2008
Fellowship, Neuro-oncology section, Samsung Medical Center, 2004-2006
Chairman, Capital armed forces hospital, 2002-2003
Residency, Department of Neurosurgery, Samsung Medical Center, 1997-2001
Internship, Samsung Medical Center, Sungkyunkwan University, 1996-1997

Professional Education

Ph.D.: Sungkyunkwan University, Korea: title "Study of response in neural stem cells after cerebral injury." (2008)
M.S.: Hanyang University, Korea (2001)
M.D.: Hanyang University, Korea (1996)

Honors & Awards

2022 Congress of Neurological Surgeons, Minimal invasive brain tumor surgery award
2016 Korean Brain Tumor Society, Best scientific award
2010 Korean Neurosurgical Society meeting, Best scientific award

2008 Korean Brain Tumor Society, Best scientific award
2007 Best Clinical Instructor in Samsung Medical Center
2006 International Metastasis Research Society, Travel scholarship award
2005 Asian Society for Neuro-Oncology (ASNO), Young Neurosurgeon award
2005 Korean Neurosurgical Society meeting, Best scientific award

Specialties & Expertise

Neurosurgery & Neuro-oncology
Endoscopic skull base surgery & Endoscopic Pituitary surgery
Brain cancer (glioblastoma, glioma), Metastatic brain tumor, Meningioma
Gamma knife radiosurgery

Present qualification

President (2018), Korean Society of Endoscopic Neurosurgery
Regulation director (2018), Korean Skull base Society
Scientific committee member (2018), Korean Brain Tumor Society

Recent Publications (*equally contributed to the work)

1. Editorial: Endoscopic transorbital surgery for skull base tumors.
A. Kong DS, Moe KS. Front Oncol. 2022 Oct 27;12:1042655. doi: 10.3389/fonc.2022.1042655. eCollection 2022.
2. Clinical and ophthalmological outcome of endoscopic transorbital surgery for cranio-orbital tumors. Kong DS, Young SM, Hong CK, Kim YD, Hong SD, Choi JW, Seol HJ, Lee JI, Shin HJ, Nam DH, Woo KI. J Neurosurg. 2018
3. Endoscopic transorbital surgery for Meckel's cave and middle cranial fossa tumors: surgical technique and early results. Jeon C, Hong CK, Woo KI, Hong SD, Nam DH, Lee JI, Choi JW, Seol HJ, Kong DS. J Neurosurg. 2018
4. Selection of endoscopic or transcranial surgery for tuberculum sellae meningiomas according to specific anatomical features: a retrospective multicenter analysis (KOSEN-002). Kong DS, Hong CK, Hong SD, Nam DH, Lee JI, Seol HJ, Oh J, Kim DG, Kim YH. J Neurosurg. 2018 May 18:1-10.
5. Is Low-Lying Optic Chiasm an Obstacle to an Endoscopic Endonasal Approach for Retrochiasmatic Craniopharyngiomas? (Korean Society of Endoscopic Neurosurgery - 003). Kim KH, Kim YH, Dho YS, Kim JH, Hong SD, Choi JW, Seol HJ, Nam DH, Lee JI, Park CK, Kong DS. World Neurosurg. 2018 Jun;114:e306-e316.

6. Reconstructive outcome of intraoperative cerebrospinal fluid leak after endoscopic endonasal surgery for tumors involving skull base. Jeon CM, Hong SD, Seol HJ, Lee JI, Nam DH, Hwang YJ, Kong DS. *J Clin Neurosci.* 2017 Nov;45:227-231.
1. Clinical outcomes of an endoscopic transclival and transpetrosal approach for primary skull base malignancies involving the clivus. Kim YH, Jeon C, Se YB, Hong SD, Seol HJ, Lee JI, Park CK, Kim DG, Jung HW, Han DH, Nam DH, Kong DS. *J Neurosurg.* 2017 Jun 2:1-9.
2. Outcome of Endoscopic Transsphenoidal Surgery for Acromegaly. Kim JH, Hur KY, Lee JH, Lee JH, Se YB, Kim HI, Lee SH, Nam DH, Kim SY, Kim KW, Kong DS, Kim YH. *World Neurosurg.* 2017 Aug;104:272-278.
3. Genomic and transcriptomic characterization of skull base chordoma. Sa JK, Lee IH, Hong SD, Kong DS, Nam DH. *Oncotarget.* 2017 Jan 3;8(1):1321-1328.
4. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee IH, Kang HJ, Rosenbloom DS, Camara PG, Liu Z, van Nieuwenhuizen P, Jung SW, Choi SW, Kim J, Chen A, Kim KT, Shin S, Seo YJ, Oh JM, Shin YJ, Park CK, Kong DS, Seol HJ, Blumberg A, Lee JI, Iavarone A, Park WY, Rabadan R, Nam DH. *Nat Genet.* 2017 Apr;49(4):594-599.
5. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Kong DS, Nam DH, Kang SH, Lee JW, Chang JH, Kim JH, Lim YJ, Koh YC, Chung YG, Kim JM, Kim CH. *Oncotarget.* 2017 Jan 24;8(4):7003-7013.
6. Analysis of risk factors to predict communicating hydrocephalus following gamma knife radiosurgery for intracranial schwannoma. Lee S, Seo SW, Hwang J, Seol HJ, Nam DH, Lee JI, Kong DS. *Cancer Med.* 2016 Dec;5(12):3615-3621.
7. Therapeutic Strategy for Cavernous Sinus-Involving Non-Functioning Pituitary Adenomas Based on the Modified Knosp Grading System. Hwang J, Seol HJ, Nam DH, Lee JI, Lee MH, Kong DS. *Brain Tumor Res Treat.* 2016 Oct;4(2):63-69.
8. Integrative radiogenomic analysis for genomic signatures in glioblastomas presenting leptomeningeal dissemination. You HJ, Park HY, Kim J, Lee IH, Seol HJ, Lee JI, Kim ST, Kong DS, Nam DH. *Medicine (Baltimore).* 2016 Jul;95(27):e4109.
9. Serial Re-Expansion of Pituitary Gland Is Associated with Endocrinologic Recovery. Cho KR, Hong SD, Hur KY, Kim ST, Seol HJ, Lee JI, Kong DS, Nam DH. *World Neurosurg.* 2016 Jun;90:496-503. doi: 10.1016/j.wneu.2016.03.050.
10. Integrative radiogenomic analysis for multicentric radiophenotype in glioblastoma. Kong DS, Kim J, Lee IH, Kim ST, Seol HJ, Lee JI, Park WY, Ryu G, Wang Z, Ma'ayan A, Nam DH. *Oncotarget.* 2016 Mar 8;7(10):11526-38. doi: 10.18632/oncotarget.7115.

11. Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide. Kong DS, Kim HR, Choi YR, Seol HJ, Lee JI, Nam DH. *J Clin Neurosci*. 2015 Sep;22(9):1425-9.
12. Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. Kim BS, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, Lee JI, Park CK, Kong DS. *J Neurooncol*. 2015 Aug;124(1):101-10.
13. Outcome of radiosurgery for recurrent malignant gliomas: assessment of treatment response using relative cerebral blood volume. *J Neurooncol*. 2015 Jan;121(2):311-8. Kim HR, Kim SH, Lee JI, Seol HJ, Nam DH, Kim ST, Park K, Kim JH, Kong DS.
14. Intraoperative visual evoked potential has no association with postoperative visual outcomes in transsphenoidal surgery. Chung SB, Park CW, Seo DW, Kong DS *Acta Neurochir (Wien)*. 2012 Aug;154(8):1505-10.
15. 3D T2-weighted turbo spin-echo MR sequence for identifying cerebrospinal fluid leak after endoscopic endonasal pituitary surgery. Chung SB, Kwag KS, Kim ST, Park K, Kim JH, Kong DS. *Acta Neurochir (Wien)*. 2012 Aug;154(8):1499-503
16. Impact of maximal safe resection on the clinical outcome of adults with craniopharyngiomas. Lee MH, Kim SH, Seoul HJ, Nam DH, Lee JI, Park K, Kim JH, Kong DS. *J Clin Neurosci*. 2012 Jul;19(7):1005-8.
17. Injectable hydroxyapatite cement patch as an on-lay graft for the sellar reconstructions following endoscopic endonasal approach. Chung SB, Nam DH, Park K, Kim JH, Kong DS. *Acta Neurochir (Wien)*. 2012 Apr;154(4):659-64
18. Clinical efficacy of radiation-sterilized allografts for sellar reconstruction after transsphenoidal surgery. Kim S, Jeon C, Kong DS*, Park K, Kim JH. *J Korean Neurosurg Soc*. 2011 Dec;50(6):503-6.
19. Leukoencephalopathy and disseminated necrotizing leukoencephalopathy following intrathecal methotrexate chemotherapy and radiation therapy for central nerve system lymphoma or leukemia. Kim JY, Kim ST, Nam DH, Lee JI, Park K, Kong DS. *J Korean Neurosurg Soc*. 2011 Oct;50(4):304-10.
20. Spontaneous intracranial hypotension: efficacy of radiologic targeting vs blind blood patch. Cho KI, Moon HS, Jeon HJ, Park K, Kong DS. *Neurology*. 2011 Mar 29;76(13):1139-44.
21. Safety of early warfarin resumption following burr hole drainage for warfarin-associated subacute or chronic subdural hemorrhage. Yeon JY, Kong DS*, Hong SC. *J Neurotrauma*. 2012 May 1;29(7):1334-41.

22. The therapeutic efficacy of fractionated radiotherapy and gamma-knife radiosurgery for craniopharyngiomas. Jeon C, Kim S, Shin HJ, Nam DH, Lee JI, Park K, Kim JH, Jeon B, Kong DS. *J Clin Neurosci*. 2011 Dec;18(12):1621-5. Epub 2011 Oct 19.
23. Endoscopic optic canal decompression for compressive optic neuropathy. Kong DS, Shin HJ, Kim HY, Chung SK, Nam DH, Lee JI, Park K, Kim JH. *J Clin Neurosci*. 2011 Nov;18(11):1541-5.
24. Efficacy of endoport-guided endoscopic resection for deep-seated brain lesions. Jo KW, Shin HJ, Nam DH, Lee JI, Park K, Kim JH, Kong DS. *Neurosurg Rev*. 2011 Oct;34(4):457-63. Epub 2011 May 26.
25. Challenging reconstructive techniques for skull base defect following endoscopic endonasal approaches. Kong DS, Kim HY, Kim SH, Min JY, Nam DH, Park K, Dhong HJ, Kim JH. *Acta Neurochir (Wien)*. 2011 Apr;153(4):807-13.
26. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, Lee JI, Park K, Kim JH, Nam DH. *Am J Neuroradiol*. 2011 Feb;32(2):382-7.
27. Impact of adjuvant chemotherapy for gliomatosis cerebri. Kong DS, Kim ST, Lee JI, Suh YL, Lim do H, Kim WS, Kwon KH, Park K, Kim JH, Nam DH. *BMC Cancer*. 2010 Aug 13;10:424.
28. Communicating hydrocephalus associated with surgery or radiosurgery for vestibular schwannoma. Jeon CJ, Kong DS*, Nam DH, Lee JI, Park K, Kim JH. *J Clin Neurosci*. 2010 Jul;17(7):862-4.
29. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH. *Neuro Oncol*. 2010 Mar;12(3):289-96.
30. Differential impact of whole-brain radiotherapy added to radiosurgery for brain metastases. Kong DS, Lee JI, Im YS, Nam DH, Park K, Kim JH. *Int J Radiat Oncol Biol Phys*. 2010 Oct 1;78(2):385-9.
31. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas. Rhee DJ, Kong DS, Kim WS, Park KB, Lee JI, Suh YL, Song SY, Kim ST, Lim DH, Park K, Kim JH, Nam DH. *Clin Neurol Neurosurg*. 2009 Nov;111(9):748-51.
32. Kong DS, Lee JI, Song SY, et al. Prognostic significance of c-Met expression for glioblastomas. *Cancer* 2009 Jan 1;115(1):140-8

33. Kong DS, Lee JI, Nam DH, et al. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. *Cancer* 2008 May 1;112(9):2046-51.
34. Kong DS, Lee JI, Nam DH, et al. Progression of gliomas is associated with cancer stem cell phenotype *Oncol Reports* 2008 Mar;19(3):639-43.
35. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Nam DH. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. *Lab Invest.* 2008 Aug;88(8):808-15
36. Kong DS, Kim MH, Jeon JW, et al. Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model *Oncol Reports* 2008 1(3): 343-346
37. Kong DS, Lee JI, Nam DH, et al. Efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: Long-term results of 125 consecutive patients treated in a single institution. *Cancer* 2007 Aug 15;110(4):854-60
38. Chun CJ, Kong DS*, Lee JI, et al. Communicating hydrocephalus associated with surgery or radiosurgery for vestibular schwannoma, *J Clinical Neurosci* 2010 Jul;17(7):862-4.
39. Yu SH*, Kong DS*, Kim JS, et al. Characteristic features of unruptured intracranial aneurysms: Predictive risk factors for aneurysm rupture. *J Neurol Neurosurg and Psychiatry* 2009 Sep 2
40. Lee DJ*, Kong DS*, Nam DH, et al. Efficacy of temozolomide as adjuvant chemotherapy for newly diagnosed glioblastomas. *Clinical Neurol and Neurosurg* 2009 Nov;111(9):748-51.
41. Park JS*, Kong DS*, Lee JA, et al. Chronologic analysis of symptomatic change following microvascular decompression for hemifacial spasm: value for predicting midterm outcome. *Neurosurg Rev.* 2008 Oct;31(4):413-9.
42. Kong DS, Lee JI, Kang SW. Gamma knife radiosurgery for choroidal hemangioma. *Am J Ophthalmol* 2007 Aug;144(2):319-22.
43. Kong DS, Hong SC, Kim JS, et al. Improvement of chronic headache after treatment of unruptured intracranial aneurysms. *Headache* 2007 May Vol. 47 (5):693-696
44. Kong DS, Park K, Nam DH, et al. Prognostic value of the lateral spread response (LSR) for intraoperative monitoring of the facial EMG during microvascular decompression for hemifacial spasm. *J Neurosurgery* 2007 Mar;106(3):384-7.
45. Kong DS, Park K, Nam DH, et al. Atypical spontaneous intracranial hypotension (SIH) with non-orthostatic headache. *Headache* 2007 Feb;47(2):199-203.

- 1. Kong DS and Nam DH Chapter 10. Metronomic chemotherapy, Springer, 2015**
- 2. Kong DS and Park K Microvascular decompression surgery Chapter 15. Perioperative Adverse Events of Microvascular Decompression: Review and a Personal Experience of 2263 Cases, Springer, 2016**
- 3. Kim ES and Kong DS. Chapter 36. Coflex, Dynamic stabilization of the spine, Thieme, 2006**